<?xml version="1.0" encoding="UTF-8"?>
<p id="para0002">The coronavirus disease (COVID-19) outbreak started in China at the end of 2019. As of April 30, 2020, there were 84,369 confirmed cases in China and 3,077,229 confirmed cases outside of China 
 <xref rid="bib0001" ref-type="bibr">[1]</xref>. The outbreak and current pandemic have attracted worldwide attention following the WHO's declaration that the outbreak was a global health emergency. The widespread and severe clinical impact of COVID-19 compelled the Chinese government to take strict measures to prevent the spread of the virus 
 <xref rid="bib0002" ref-type="bibr">[2]</xref>. In addition to the development of therapeutic agents against SARS-CoV-2, there is an urgent need to development an efficacious vaccine to combat the rapid spread of SARS-CoV-2. Since the birth of the first vaccine in 1796, vaccines have profoundly reduced the prevalence and fatality rates of various infectious diseases, including measles and smallpox 
 <xref rid="bib0003" ref-type="bibr">[3]</xref>. Owing to rapid advances in technology, novel materials have been employed for vaccine preparation, such as virus-like particles (VLPs). For example, a VLP-based HPV vaccine, which is now commercially available, has improved HPV prevention.
</p>
